

Introduction

- Statin-induced adverse events (AEs) may prompt additional pharmacotherapy resulting in prescribing cascades (PCs)
- We previously performed untargeted prescribing cascade signal detection using high throughput sequence symmetry analysis (HTSSA), identifying 160 statin-related PC signals (57 plausibly true PCs after expert review)
- However, HTSSA is computationally complex, and false positive signals are common
- Herein, we evaluated whether a targeted approach – informed by the Side Effect Resource (SIDER), a public database containing pharmaceutical package inserts data – captures similar findings more efficiently

Methods

- The SIDER database contains medication names, classified by Anatomical Therapeutic Chemical level 4 (ATC₄) codes, as well as AEs and indications of medications classified by Medical Dictionary for Regulatory Activities (MeDRA) codes, all collated from publicly available drug labelling
- We identified all MeDRA codes representing statin-related AEs from SIDER; for each MeDRA code, we identified all ATC₄ codes for which the MeDRA code was an indication (see **Figure 1** for an example)
- MeDRA codes were then dropped, leaving 'statin—other medication class' potential prescribing cascade signals.
- These signals were compared to empirically-derived signals from claims-based HTSSA (gold standard) to calculate sensitivity and specificity for SIDER signal detection

Conclusion

- SIDER predicted plausibly true statin-related PCs that were empirically identified (and expert-reviewed) from HTSSA, with low specificity (31.5%) but high sensitivity (80.7%)
- However, 18% (n=79) of predicted signals were clinically implausible PCs or likely attributable to disease progression or therapeutic escalation
- Although SIDER proved to be useful in identifying statin-related prescribing cascade signals, it is unlikely to be suitable as an efficient stand-alone tool due to its low specificity and clinically implausible signals

Table 1: Signal comparison between HTSSA and SIDER

		Claims-Based HTSSA (Gold standard)	
		Positive Signal	No Signal
SIDER	Positive Signal	125	251
	No Signal	35	128

Figure 1: Example of SIDER linkage to identify statin-related prescribing cascade signals





Table 2: Comparison between plausible prescribing cascades detected by HTSSA and SIDER

		Claims-Based HTSSA (Gold standard)	
		Positive Signal	No Signal
SIDER	Positive Signal	46	330
	No Signal	11	152

Figure 2: SIDER signals classified by ATC 1 marker class levels



Results

- We detected 432 potential signals using SIDER, compared to 160 empirically-identified signals using HTSSA screening, with a sensitivity of 78.1% (125 of 160 positive signals) and specificity of 33.8% (128 of 379 non-signals)
- To assess predictive ability of SIDER, signals were screened to capture the 57 plausibly true PCs which were empirically derived from HTSSA and reviewed by clinical experts
- Of these, 46 were predicted using SIDER with a sensitivity of 80.7% and specificity of 31.5%
- Conversely, SIDER predicted 79 signals that represented therapeutic escalation, disease progression or clinically implausible prescribing cascades for statins

Limitations and Discussion

- SIDER was last updated in 2015 and, thus, does not capture newer drug classes, recently discovered AEs, or recently-approved indications, reducing its ongoing utility in detecting prescribing cascade signals
- Our overall findings suggest that when combined with clinical expert review, medication package inserts could potentially prove to be a valuable resource to identify statin-related PCs if they are collated using ATC and MeDRA codes
- More updated data resources like U.S. FDALabel could prove to be a useful alternative but require further processing (e.g., with natural language processing) for use in cases such as this